8-K: Catheter Precision Secures $1.5 Million Investment via Convertible Preferred Stock and Warrants

Catheter Precision, Inc. has entered into a Securities Purchase Agreement to raise $1.5 million through the sale of Series B Convertible Preferred Stock and the issuance of Series L warrants.

Summary

• Catheter Precision, Inc. has secured a $1.5 million investment through a Securities Purchase Agreement.
• The agreement involves the sale of Series B Convertible Preferred Stock and the issuance of Series L warrants to three investors.
• An additional 1.5 million shares of Series B Convertible Preferred Stock were issued in exchange for existing senior secured Convertible Promissory Notes of QHSLab, Inc.
• Up to 8,574,000 shares of common stock are reserved for issuance upon conversion of the Series B Convertible Preferred Stock, with each share potentially converting into approximately 2,858 shares of common stock.
• The Series L warrants allow the investors to purchase up to 4,285,716 shares of Company common stock.
• The Series B Convertible Preferred Stock has a fixed conversion price of $0.35 per share of common stock.
• The Series L warrants are exercisable at $0.50 per share and are callable by the Company if the stock price exceeds $1.50.
• Stockholder approval is required for the exercise of warrants and conversion of preferred stock beyond a certain threshold, with a meeting planned for July 25, 2025.
• The company acquired QHSLab notes with an estimated value of $1.6 million in exchange for preferred stock.
• The company has agreed to file a resale registration statement with the SEC by May 27, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company has secured funding, but there are risks associated with the QHSLab notes and the need for stockholder approval. The terms of the financing are fairly standard, suggesting a reasonable deal for both the company and investors.

Positives

• The company has secured a $1.5 million investment, strengthening its financial position.
• The Series L warrants have a call provision that could benefit the company if the stock price increases.
• The acquisition of QHSLab notes could provide additional value to the company.

Negatives

• Stockholder approval is required for the exercise of warrants and conversion of preferred stock beyond a certain threshold, which introduces uncertainty.
• The Series L warrants have a call provision that could limit potential gains for warrant holders if the stock price increases significantly.
• The QHSLab notes are currently in default, and there is no assurance that they will be paid in full or at all.

Risks

• The QHSLab notes are currently in default, and their valuation is uncertain.
• The company needs to obtain stockholder approval for the exercise of warrants and conversion of preferred stock beyond a certain threshold.
• The company's stock price may be negatively impacted by the issuance of new shares upon conversion of the preferred stock and exercise of the warrants.
• The company's ability to meet its obligations under the Securities Purchase Agreement is subject to certain conditions, including the accuracy of representations and warranties and the performance of covenants.

Future Outlook

The company intends to seek stockholder approval at its Annual Meeting of Stockholders to be held on July 25, 2025. The Company has agreed to file a resale registration stated with the Securities and Exchange Commission no later than May 27, 2025.

Industry Context

The announcement reflects a common financing strategy for small-cap companies, utilizing convertible securities and warrants to attract investment. The success of this strategy depends on the company's ability to achieve its operational goals and increase its stock price, benefiting both the company and the investors.

Comparison to Industry Standards

• Comparable companies in the medical device industry, such as AngioDynamics and Spectranetics (prior to its acquisition by Philips), have utilized similar financing methods, including convertible debt and equity offerings, to fund research and development, acquisitions, and general corporate purposes.
• The terms of the Series B Convertible Preferred Stock, including the conversion price and dividend rights, are generally consistent with industry standards for similar financings.
• The exercise price and call provisions of the Series L warrants are also within the typical range for warrants issued in connection with equity and debt offerings.
• The requirement for stockholder approval for the conversion and exercise of securities beyond a certain threshold is a common provision to protect existing shareholders from excessive dilution.

Stakeholder Impact

• Shareholders may experience dilution upon conversion of the preferred stock and exercise of the warrants.
• Employees may benefit from the increased financial stability of the company.
• Customers may benefit from the company's ability to invest in research and development and improve its products and services.
• Suppliers may benefit from the company's increased financial stability and ability to pay its bills.
• Creditors may be impacted by the issuance of new debt and equity securities.

Next Steps

• The company needs to file a resale registration statement with the SEC by May 27, 2025.
• The company needs to obtain stockholder approval for the exercise of warrants and conversion of preferred stock beyond a certain threshold at the Annual Meeting of Stockholders on July 25, 2025.
• The company needs to monitor the performance of the QHSLab notes and take appropriate action if necessary.

Key Dates

Keywords

Series B Convertible Preferred Stock, Series L Warrants, Securities Purchase Agreement, Capital Raise, Stockholder Approval, QHSLab Notes, Registration Rights, Catheter Precision